Providers/Grant Support
This activity is supported by an independent medical educational grant from Immunocore.
Credits Available
Physicians—maximum of 1.0 AMA PRA Category 1 Credit(s).
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is intended for ophthalmology, ocular oncology, and medical oncology physicians, APPs, nurses, and other members of the health care team who care for patients with metastatic uveal melanoma (mUM).
Program Overview
In this expert roundtable, oncology and ocular specialists dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts to life, with special attention to application in VA and academic settings. Whether you're a medical oncologist, ocular oncologist, ophthalmologist, or APP, this discussion is designed to sharpen your skills and your care aligned with the latest science.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Differentiate uveal from cutaneous melanoma
- Explain the importance of HLA typing in patients with uveal melanoma
- Explain the mechanism of action of novel bispecific TCR therapy
- Interpret efficacy and safety clinical trial data on the use of bispecific TCR therapy in patients with mUM
Faculty
Gregory Daniels, MD, PhD – Planner and Faculty
Professor of Medicine
Department of Medicine
Moores Cancer Center
University of California, San Diego
San Diego, CA
Jesse Keller, MD – Planner and Faculty
Assistant Professor of Medicine
John T. Milliken Department of Medicine
Division of Oncology
WashU Medicine
St. Louis, MO
Marlana Orloff, MD – Planner and Faculty
Associate Professor of Medical Oncology
Alexander & Johnston Family Endowed Clinical Director of Uveal Melanoma
Co-Director Melanoma Research Institute of Excellence
Department of Medical Oncology
Thomas Jefferson University Hospital
Philadelphia, PA
Melissa Glasner, MS – Planner and Reviewer
Medical Writer
The France Foundation
Old Lyme, CT
Accreditation Statement
This activity is jointly provided by The France Foundation and the Association of VA Hematology/Oncology.
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the Association of Hematology/Oncology (AVAHO). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Physician Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
Marlana Orloff, MD
Non-CE Consulting: Delcath, Ideaya, Immunocore, Replimune, Trisalus
Contract Research: Delcath, Ideaya, Immunocore, iOnctura, Iovance, Replimune, Regeneron, Trisalus
- All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member
- Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Gregory Daniels, MD, PhD
No relevant financial disclosures
Jesse Keller, MD
No relevant financial disclosures
Melissa Glasner, MS
No relevant financial disclosures
Activity staff at The France Foundation and AVAHO have no relevant financial disclosures.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the post-test is required to successfully complete this activity. The participant may take the test until successfully passed.
Credit Fulfillment
- If you are requesting AMA credits or a certificate of participation, your certificate will be available for download
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, and Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF and AVAHO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and AVAHO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation and AVAHO present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, AVAHO, and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or [email protected].